Insider Selling: Voyager Therapeutics (NASDAQ:VYGR) CEO Sells $44,547.57 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 11,511 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total transaction of $44,547.57. Following the completion of the transaction, the chief executive officer directly owned 472,549 shares of the company’s stock, valued at $1,828,764.63. This trade represents a 2.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alfred Sandrock also recently made the following trade(s):

• On Tuesday, February 24th, Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock. The stock was sold at an average price of $3.79, for a total value of $53,806.63.
• On Tuesday, February 10th, Alfred Sandrock sold 12,192 shares of Voyager Therapeutics stock. The stock was sold at an average price of $3.78, for a total value of $46,085.76.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR opened at $3.96 on Monday. Voyager Therapeutics, Inc. has a 1 year low of $2.64 and a 1 year high of $5.55. The stock has a market cap of $236.02 million, a price-to-earnings ratio of -1.95 and a beta of 1.38. The stock has a 50-day moving average price of $3.92 and a two-hundred day moving average price of $4.18.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.08. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.The company had revenue of $13.46 million during the quarter, compared to the consensus estimate of $10.49 million. Sell-side analysts forecast that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wexford Capital LP bought a new stake in Voyager Therapeutics in the 3rd quarter valued at approximately $42,000. ProShare Advisors LLC bought a new position in shares of Voyager Therapeutics during the 4th quarter worth approximately $44,000. CIBC Asset Management Inc acquired a new stake in shares of Voyager Therapeutics in the fourth quarter valued at approximately $45,000. Coldstream Capital Management Inc. bought a new stake in shares of Voyager Therapeutics in the third quarter worth $55,000. Finally, EHP Funds Inc. bought a new stake in shares of Voyager Therapeutics in the third quarter worth $58,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on VYGR shares. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, March 17th. Wall Street Zen raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Truist Financial upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Voyager Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.